GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensorion SA (XPAR:ALSEN) » Definitions » Institutional Ownership

Sensorion (XPAR:ALSEN) Institutional Ownership : 2.10% (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sensorion Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sensorion's institutional ownership is 2.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sensorion's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sensorion's Float Percentage Of Total Shares Outstanding is 0.00%.


Sensorion Institutional Ownership Historical Data

The historical data trend for Sensorion's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensorion Institutional Ownership Chart

Sensorion Historical Data

The historical data trend for Sensorion can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 1.99 1.96 0.83 0.84 0.86 0.83 0.83 0.85 3.09 2.10

Sensorion Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Sensorion (XPAR:ALSEN) Business Description

Traded in Other Exchanges
Address
375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of therapies to restore, treat and prevent hearing loss. The company's product is in phase 2 clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies.

Sensorion (XPAR:ALSEN) Headlines

No Headlines